Andrews Chap 32-Cutaneous Lymphoid Hyperplasia, Cutaneous T-Cell Lymphoma, Other Malignant Lymphomas, and Allied Diseases

Cutaneous Lymphoid Hyperplasia and Lymphomas

1. Overview of Cutaneous Lymphoid Hyperplasia

  • Definition: Cutaneous lymphoid hyperplasia refers to benign proliferations of lymphoid tissue in the skin.

  • Causes: Can be associated with reactions to medications, infections, arthropod bites, or can be idiopathic.

  • Histological features: Generally shows a lack of clonality; however, monoclonal variants can occur.

2. Histological Examination

  • Nodular Pattern:

    • Most common in adults, especially women; presents on the face as solitary or grouped asymptomatic papules or nodules.

    • Histologically presents as dense infiltrate primarily in dermis.

  • Reactive Adnexal Hyperplasia: Commonly found in lymphoid hyperplasia.

3. Clinical Manifestations

  • Symptoms: Usually asymptomatic, but may be related to infection or medication. Occasionally, regional lymphadenopathy.

  • Borrelia-induced Lymphoid Hyperplasia: Occurs in young women, typically on earlobes/nipples.

4. Diagnosis and Confirmation

  • Diagnostic Tests: Elevated anti-Borrelia antibody tests and detection of borrelial DNA in afflicted tissue confirm diagnosis.

  • Histological Characteristics: Infiltrate is composed of various lymphocytes, histiocytes, plasma cells, eosinophils, with often well-defined germinal centers.

5. Treatment Options

  • General Treatment:

    • Usually unnecessary unless symptomatic.

    • Discontinuation of implicated medications if present.

    • Treatments include topical corticosteroids, cryosurgery, and in severe cases, localized surgical excision.

  • Intralesional Steroids: Occasionally beneficial but recurrence can happen.

6. Cutaneous T-Cell Lymphoma (CTCL)

  • Definition: Malignant neoplasm predominantly composed of T lymphocytes.

  • Types: Includes mycosis fungoides, Sézary syndrome, lymphomatoid papulosis, and other non-mycosis forms.

7. Mycosis Fungoides (MF)

  • Incidence: Seen in 1 in 300,000 annually; more common in black males.

  • Stages:

    • Patch Stage: Starts as flat patches; serious difficulty in early diagnosis due to common presentation.

    • Plaque Stage: Lesions become infiltrated with significant dermatologic changes.

    • Tumor Stage: Formation of nodules and/or ulceration.

8. Diagnosis and Staging of MF

  • Staging System: Based on skin (T), lymph nodes (N), and blood (B) involvement.

    • Examples of stages include:**

      • Stage IA: T1, N0, M0

      • Stage IIB: T3, N0-N1, M0

      • Stage IVB: T1-T4, N0-N3, M1

  • Pathological Evaluation: Essential to confirm diagnoses in equivocal cases, possibly involving flow cytometry and TCR gene rearrangement analysis.

9. Treatment of MF

  • General Management Strategies:

    • Immunomodulatory therapies, topical agents, phototherapy, and chemotherapy may all play a role based on individual patient staging and responsiveness.

    • Specific agents include corticosteroids, topical nitrogen mustard, and IFN-α.

    • Biologic Response Modifiers: e.g., resiquimod shows potential in CTCL management.

  • Radiation Therapy: Total-skin electron beam therapy is effective for several stages of MF.

10. Other Malignant Lymphomas

  • Angioimmunoblastic T-Cell Lymphoma: Characterized by features like fever, weight loss, and a distinctive skin rash.

  • CD30-Positive Lymphoproliferative Disorders: Includes anaplastic large cell lymphomas with typically good prognosis, but need monitoring for transformation over time.

11. Importance of Ongoing Research and Treatment Evaluation

  • Continuous adaptations in staging, diagnostic procedures, and treatment can significantly improve patient outcomes in cutaneous lymphoproliferative disorders.